- Home
- Platform
- Services
- Protein Engineering Directed Evolution Services
- Protein Engineering Rational Design Services
- Protein Synthesis Services
- Protein Modification Services
- Solutions
- COMPANY
Over the past decade, recombinant antibody engineering has emerged as one of the most promising approaches for molecular design, selection, and production for basic research, medicine, and the pharmaceutical industry. With its advanced protein engineering platform established over the years, Creative BioMart has successfully produced a variety of highly specific recombinant antibodies for the search for novel therapeutics with enhanced immune protection. Our scientists are committed to providing fully customized therapeutic antibody production solutions to customers around the world.
Hundreds of monoclonal antibodies (mAbs) and proteins partially derived from mAbs are in production and used in a wide variety of therapeutic applications. Currently, there are more than 65 monoclonal antibodies approved on the market for the treatment of various diseases, mainly cancer, which has led to strong innovation in antibody production and engineering. However, some clinical humanized or chimeric murine antibodies have several limitations and complexities. A variety of protein engineering techniques have emerged that can be applied to antibodies to improve their affinity and/or biophysical properties, allowing the production of highly specific recombinant antibodies. These techniques are becoming increasingly popular in the biopharmaceutical industry because they are high-throughput and allow complete control over the characteristics of protein sequences during the development phase of biotherapeutics. In recent years, the development of polyclonal and monoclonal antibodies through experimental animals has become an important way to prevent a variety of pathogenic infectious diseases.
Fig 1. Applications of molecular biology during the engineering of antibody therapeutics. (Chiu ML, et al., 2016)
Therapeutic antibodies are bulky macromolecules that present challenges in construction, optimal pharmacokinetics, manufacturing, stability, and process development. Creative BioMart has successfully utilized a variety of protein engineering techniques to find novel therapeutics with enhanced immune protection. We can help you develop high-affinity antibodies with immune effector functions, efficient development of fusion proteins, efficient tumor and tissue penetration, and conserved targets.
It is known that antibody fragments often display similar binding properties to their full-length versions, with better biophysical properties. In addition, various protein engineering screening techniques are available for antibody fragments but not full-length antibodies. Therefore, our scientists have chosen a strategy to improve full-length antibodies in the form of antibody fragments. Our therapeutic antibodies are used in the study of various diseases (eg, cancer, metabolic and hormonal disorders, pathogen infections), as well as in the analysis of patient antibody profiles and anti-idiotypic inhibition. The advantages of our strategy are:
(1) Antibody fragments lack constant regions and are less immunogenic.
(2) Higher tumor penetration.
(3) Cheaper and larger scale bacterial production.
(4) Various in vitro display techniques can be used to improve several properties of antibodies.
In order to provide customized high-quality therapeutic antibodies to our global customers, we use mouse hybridoma technology to produce therapeutic antibodies. In addition, we utilize advanced protein engineering techniques to discover and/or improve therapeutic antibodies.
We have applied phage display, ribosome and mRNA display, bacterial surface display, yeast surface display and mammalian display technologies to variable fragments of antibodies, and have demonstrated many different antibody fragment formats through these technologies.
The aggregation, solubility and stability of antibodies are important factors affecting the development of antibodies. This will result in reduced antigen-binding affinity, immunogenic responses, and wasted resources during protein production. Our scientists use a variety of rationally designed network tools to improve the desired properties of therapeutic antibodies, including improving affinity/specificity or preventing aggregation and increasing solubility and stability without altering affinity/specificity.
Creative BioMart has in-depth knowledge and experience of the tools and processes involved in antibody development, and provides professional solutions for therapeutic antibody production. Whether your antibodies are in the discovery and screening stages, or are planning antibody drug production, please contact us to discuss further details to ensure your next success.
References